Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.

Autor: Fisher BA; Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; NIHR Birmingham Biomedical Research Centre, Birmingham, UK., Mariette X; Department of Rheumatology, Université Paris-Saclay, Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, INSERM UMR1184, Le Kremlin Bicêtre, France., Papas A; Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, USA., Grader-Beck T; Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Bootsma H; Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands., Ng WF; NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK., van Daele PLA; Department of Internal Medicine, Erasmus MC, Rotterdam, Netherlands., Finzel S; Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Noaiseh G; Division of Allergy, Clinical Immunology and Rheumatology, Department of Medicine, University of Kansas, Kansas City, KS, USA., Elgueta S; Department of Rheumatology, Clinica Alemana de Valdivia, Valdivia, Chile; Clinical Research Chile SpA, Biomedical Research Centre, Valdivia, Chile., Hermann J; Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria., McCoy SS; University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Akpek E; Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Bookman A; Toronto Western Hospital, Toronto, ON, Canada., Sopala M; Novartis Pharma, Basel, Switzerland., Montecchi-Palmer M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Luo WL; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Scheurer C; Novartis Pharma, Basel, Switzerland., Hueber W; Novartis Pharma, Basel, Switzerland. Electronic address: wolfgang.hueber@novartis.com.

Publikováno v: Lancet (London, England) [Lancet] 2024 Aug 10; Vol. 404 (10452), pp. 540-553. Date of Electronic Publication: 2024 Jul 31.

Modulation dose-dépendante des signatures protéomiques par le ianalumab chez les patients atteints de la maladie de Sjögren

Autor: Mariette, X., Verstappen, G.M., Bootsma, H., Finzel, S., Grioni, A., Fisher, B., Papas, A., Celine, R., Avrameas, A., Tuckwell, D., Zierer, J., De Luca, V., Ferrero, E., Bonal, C., Dacosta, A., Hillenbrand, R., Isnardi, I., Hueber, W.

Publikováno v: In La revue de médecine interne June 2024 45 Supplement 1:A56-A57

Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's.

Autor: Cooper C; Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK., Wratten S; Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK., Williams-Hall R; Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK., Bookman AAM; Division of Rheumatology, Toronto Western Hospital/UHN, University of Toronto, Toronto, ON, Canada., Ndife B; Department of US Oncology HEOR, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Hueber W; Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland., Goswami P; Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland. pushpendra.goswami@novartis.com.

Publikováno v: Rheumatology and therapy [Rheumatol Ther] 2022 Dec; Vol. 9 (6), pp. 1499-1515. Date of Electronic Publication: 2022 Sep 16.

Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? - Authors' reply.

Autor: Bowman SJ; Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK; Institute of Inflammation and Ageing, College of Medical and Dental Sciences and National Institute for Health Research Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK; Rheumatology Department, Milton Keynes University Hospital, Milton Keynes, UK. Electronic address: simon.bowman@uhb.nhs.uk., Dorner T; Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany., Mariette X; Université Paris Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, INSERM U1184, Le Kremlin Bicêtre, France., Luo WL; Novartis Pharmaceuticals, East Hanover, NJ, USA., Hueber W; Novartis Pharma, Basel, Switzerland.

Publikováno v: Lancet (London, England) [Lancet] 2022 Sep 10; Vol. 400 (10355), pp. 808-809.

Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197.

Autor: De Buck, S¹, Hueber, W², Vitaliti, A³, Straube, F⁴, Emotte, C⁵, Bruin, G¹, Woessner, R¹

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology. Dec2015, Vol. 4 Issue 12, p691-700. 10p.